Private equity acquisitions—notably roll-up strategies—continued to face antitrust scrutiny in 2024. As did serial acquisitions by non-PE acquirers. Headwinds were particularly strong in the U.S., but ...

The number of U.S. opioid treatment programs acquired by private equity firms grew from five in 2011 to 358 by 2022. This study showed that private equity acquisition of opioid treatment programs did ...

Patient care experiences worsened after private equity firms took over hospitals, according to a difference-in-differences analysis. From 2008 to 2019, the percentage of patients rating hospitals a 9 ...

Following private equity acquisition, hospitals reduced salaries and staffing in emergency departments (EDs) and intensive care units (ICUs) relative to non-acquired hospitals, a matched difference-in ...

Private equity acquisitions of hospitals have raised concerns about their impact on patient care experience, with mixed evidence on quality and outcomes. The study analyzed 73 private equity-acquired ...

The FTC is actively pursuing enforcement through litigation, as evidenced by a recent case against a portfolio company, alleging an anti-competitive scheme to roll-up anesthesia practices in Texas and ...